Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01604278 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

449

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: NVA237 50 µg and indacaterol 150 µg
DRUG: Placebo to NVA237 and indacaterol 150 µg

Sponsor

Novartis Pharmaceuticals